SCHEMBL2585010

SCHEMBL2585010

N#Cc1ccc(Cc2ccccc2O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.63
HSPA5 P11021 1/20 0.54
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
LOXL2 Q9Y4K0 2/20 0.46
SAE1 Q9UBE0 1/20 0.45
UBA2 Q9UBT2 1/20 0.45
CYP2A6 P11509 1/20 0.44
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA6 P23280 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
BCL2 P10415 1/20 0.42
BCL2L1 Q07817 1/20 0.42
ALOX5 P09917 1/20 0.42
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9776607 0.84 KEAP1 (0.86) KEAP1HSPA5CA12CA2CA9
SCHEMBL30616875 0.84 KEAP1 (0.86) KEAP1HSPA5CA12CA2CA9
SCHEMBL8702909 0.84 TAAR1 (0.46) KEAP1HSPA5LOXL2CYP2A6CA12
SCHEMBL7031631 0.81 KEAP1 (0.63) KEAP1HSPA5CA12CA2BCL2
SCHEMBL4003141 0.81 KEAP1 (0.63) KEAP1HSPA5CA12CA2BCL2
Water SCHEMBL27955473 0.80 KEAP1 (0.72) KEAP1HSPA5BCL2BCL2L1ALOX5
SCHEMBL68653 0.78 KEAP1 (1.00) KEAP1HSPA5BCL2BCL2L1ALOX5
SCHEMBL8925742 0.78 KEAP1 (0.76) KEAP1HSPA5CA12CA2CA9
SCHEMBL29506902 0.78 KEAP1 (1.00) KEAP1HSPA5BCL2BCL2L1ALOX5
SCHEMBL6532341 0.78 LOXL2 (0.48) CYP11B1CYP11B2LOXL2SAE1UBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192231-A Copper-based complex Cu (dppf) (BH)4) Application in nucleophilic addition reaction of arylboronic acid 安徽大学 2025-06-24 CN disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
CN-113784950-A Novel thyromimetic agents 速通医疗公司 2021-12-10 CN disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 US disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 US disclosed
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667606-B2 Thyromimetics TPO, TSHR, TTR KEAP1 2106/4885HSPA5 3213/4885CYP11B1 301/4885
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 KEAP1 901/4885HSPA5 2445/4885CYP11B1 12/4885
US-20210053917-A1 NOVEL THYROMIMETICS TPO, TSHR, CHRM1 KEAP1 1628/4885HSPA5 2993/4885CYP11B1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.